Medidata Hosts 12th NEXT China Annual Conference in Shanghai, Showcasing AI-Driven Digital Innovation Across the Drug Development Lifecycle
Shanghai, China, September 7—Hosted by Medidata, a wholly-owned subsidiary of Dassault SystèmesThe 12th NEXT China Annual ConferenceGrandly Held. Medidata NEXT is Medidata’s global annual conference, with the China Annual Meeting serving as a key stop. After a three-year hiatus, it has once again been launched in person with great fanfare.
Centered on the theme “Uniting Hearts and Minds, Envisioning the Future,” the grand event has extended prestigious invitations to nearly 30 heavyweightGuests, focusing on “A Risk-Controllable, Intelligent Patient Journey”、“AI-Driven Data Management and Insights" and "Intelligent Drug R&D”Three Major Themes: Sharing Digital Innovation Achievements Across the Full Life Cycle and Jointly Exploring the Development Direction of Digital and Intelligent Applications in the Life Sciences Industry.
Guests on site jointly launched the 12th Medidata NEXT China Annual Conference, with a unique opening ceremony.
Gathering Elites to Explore the Future of Digital Intelligence Innovation
At this grand event, leading experts from the life sciences industry delivered nearly 30 compelling presentations to attendees. At the opening of the conference, Medidata’s Senior Vice President, AsiaGeneral Manager, Greater China RegionEdwin NGMr. [Name] shared Dassault Systèmes’ Life Sciences business unit’s strategic layout and the value of its end-to-end solutions; Senior Vice President of Medidata and Global Head of Medidata AIFareed MelhemMr. [Name] and Senior Vice President of Product Support and Operations at MedidataJeff VentimigliaFirstMr. Sheng first shared his insights under the title “Leveraging Digital and Intelligent Innovation to Propel a New Era in Pharmaceutical R&D.”
Subsequently, the Vice President of Global Drug Safety at Junshi BiosciencesZhan XiaojingSharing Junshi Biosciences’ Innovative Applications in Clinical Trials: Rooted in China, with a Global Footprint; Director of the Department of Oncology, Shanghai East Hospital Affiliated to Tongji University, and Chairman of the East Clinical Oncology Research CenterLi JinFrom the perspective of research institutions, the professor affirmed the inevitability of the digital and intelligent transformation of clinical trials and introduced a groundbreaking new model of local collaboration with Medidata for oncology trials. He serves as the Chairman of the Biostatistics Expert Committee of the Chinese Society of Clinical Oncology (CSCO) and is affiliated with the Air Force Medical University.Xia JielaiThe professor provided an in-depth analysis of the policy environment surrounding the digitalization of clinical trials, as well as the application of advanced analytics in clinical research.
In the afternoon, at two parallel sessions titled “Intelligent Patient Journeys with Controllable Risks” and “AI-Driven Data Management and Insights,” dozens of experts delivered accessible yet in-depth presentations on the practical application of digital solutions such as DCT (decentralized clinical trials), eCOA (electronic clinical outcome assessments), RTSM (randomization and trial supply management), and RBQM (risk-based quality management), as well as focal topics including Medidata AI’s optimization of trial design and acceleration of site selection.
Combining the hands-on guides for solutions such as Rave EDC, RTSM demo, and Knowledge Hub from the “Practical Operation Demonstration” breakout session, the entire conference seamlessly integrated theory with practice, demonstrating genuine commitment.
Dassault Systèmes’ Life Sciences business unit has extended its digital and intelligent innovation across the entire lifecycle, from drug discovery to manufacturing and market launch. Speakers at the “Digital and Intelligent Drug R&D” sub-forum delivered presentations on topics such as the development and future of new biopharmaceutical technologies, as well as the construction and practical implementation of smart, digital laboratories. They highlighted solutions including BIOVIA ONE Lab, Electronic Laboratory Notebook (ELN) systems, and Discovery Studio, sharing cutting-edge insights into digital and intelligent applications in the drug discovery phase. The discussions emphasized how these technologies accelerate innovative drug R&D and enhance laboratory quality management, outlining the trajectory for improving the efficiency and quality of China’s innovative drugs through digital and intelligent tools.
Deepening Our Roots in China to Accelerate the Development of Locally Innovative Drugs
MedidaSince its entry into the Chinese market in 2015, Medidata has witnessed China’s new drug R&D capabilities ascend to the global second tier, with domestic pharmaceutical companies rising with unstoppable momentum. By partnering with nearly 600 pharmaceutical companies and more than 40 contract research organizations (CROs) in China, Medidata China has supported over 3,160 clinical trials, involving a total of 480,000 patients and healthy volunteers, thereby establishing itself as a key leader in the digital transformation of the life sciences sector in China.
Ms. Li Wei, Vice President and General Manager of Greater China at Medidata, Delivered Opening Remarks
Vice President, Medidata Greater ChinaGeneral ManagerLi WeiFemaleShi stated:
“In recent years, supported by national policies, China’s healthcare industry has entered a phase of rapid development. Medidata has been deeply engaged in the digital and intelligent transformation of life sciences, and we are honored to have witnessed and contributed to the industry’s ‘takeoff.’”
Currently, four domestically produced PD-1 inhibitors have been successfully included in China’s National Reimbursement Drug List, with the development of these drugs supported by Medidata technologies. While empowering local innovation, Medidata also supports the global expansion of Chinese innovative drugs, including the first Chinese innovative drug approved for marketing by the U.S. FDA, as well as all 23 major Chinese[1]License-Out Innovative Drug Development.
This year, Medidata achieved two major milestones: supporting over 30,000 clinical trials and reaching more than 9 million patients. By leveraging global resources and technology, we will continue to uphold our steadfast commitment of “In China, For China,” safeguarding pharmaceutical R&D innovation for our customers in China and helping more medical innovations benefit patients.
[1] 23 large-scale transaction items, each with a transaction amount exceeding $500 million